May 2026
1. LU Y, Lin K, Wang Q, Huang X, et al
   NAT10/ac(4)C drives intrahepatic cholangiocarcinoma by suppressing transposable elements via chromatin remodeling.
   Proc Natl Acad Sci U S A. 2026;123:e2532263123.
   

   >> Share

   
   
2. CHEN L, Wang D, Qin W, Wang G, et al
   Mitochondrial fusion heterogeneity drives bidirectional tumor phenotypic transition in combined hepatocellular-cholangiocarcinoma.
   Proc Natl Acad Sci U S A. 2026;123:e2521310123.
   

   >> Share

   
   October 2025
3. CRELLEN T, Vita F, Braconi C, Sithithaworn P, et al
   Natural history of liver fluke infection underpins epidemiological patterns of biliary cancer.
   Proc Natl Acad Sci U S A. 2025;122:e2423536122.
   

   >> Share

   
   September 2025
4. YANG W, Wang S, Ji S, Wang J, et al
   CRISPR screens identify the ATPase VCP as a druggable therapeutic vulnerability in cholangiocarcinoma.
   Proc Natl Acad Sci U S A. 2025;122:e2519568122.
   

   >> Share

   
   February 2024
5. SCHONHERR H, Ayaz P, Taylor AM, Casaletto JB, et al
   Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2.
   Proc Natl Acad Sci U S A. 2024;121:e2317756121.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share